Clincosm LogoSign in Get a demo

Role of Airway Hyperresponsiveness on Performance in Elite Swimmers.

Sponsor
Laval University (Other)
Overall Status
Completed
CT.gov ID
NCT00876135
Collaborator
(none)
57
Enrollment
1
Location
1
Arm
53
Duration (Months)
1.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The prevalence of airway hyperresponsiveness (AHR) is very high in elite swimmers, reaching 80% in certain studies. Repeated Chlorine-derivatives exposure may be a major causative factor for its development. Asthma diagnosis is generally made on the basis of clinical characteristics. The demonstration of a variable bronchial obstruction through positive expiratory flow reversibility to a bronchodilator, spontaneous variations of airway obstruction or a positive provocation test (methacholine, eucapnic voluntary hyperpnoea…) is necessary to avoid false diagnosis. Currently asthma treatment in swimmers is the same as in the general population. A short-acting bronchodilator is often prescribed to avoid occasional symptoms, combined with an inhaled corticosteroid or an antagonist of Leukotriene if asthma symptoms are persistent. Previous studies have shown a reduced efficiency for asthma medication in elite athletes compared with non-athletes. The specific response to different medications remains to be studied in athletes. The effects of a short-acting bronchodilator in swimmers with AHR, especially when asymptomatic, on pulmonary function and performance have not yet been studied. Moreover, the significance of a positive bronchial provocation test remains to be studied in asymptomatic swimmers with AHR.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

Our hypothesis is that swimmers with a positive bronchial provocation challenge have not necessarily an exercise-induced bronchoconstriction during swimming and the use of a bronchodilator will be unnecessary. Chlorine-derivatives exposure may be responsible for a weakness of the epithelium layer but warm and humid atmosphere of the swimming-pools may be protective for the development of a bronchoconstriction. Thus we also hypothesis that during a field test outside the swimming pool, swimmers will develop an exercise-induced asthma, and will need to take a bronchodilator in prevention.

Study Design

Study Type:
Interventional
Actual Enrollment :
57 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Primary Purpose:
Diagnostic
Official Title:
Role of Airway Hyperresponsiveness on Performance in Elite Swimmers: Efficiency of a Bronchodilator to Prevent an Exercise-induced Bronchoconstriction
Study Start Date :
Dec 1, 2008
Actual Primary Completion Date :
May 1, 2013
Actual Study Completion Date :
May 1, 2013

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Inhaled Bronchodilator

Drug: Ventolin
Ventolin or Placebo will be given before the 4 field tests (2 with ventolin in prevention and 2 with placebo in prevention) and 2 eucapnic voluntary hyperpnoea tests (one preceded by Ventolin and one preceded by Placebo).
Other Names:
  • Ventolin (salbutamol)

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Bronchodilator versus placebo effects on performance [march to may 2009/ 8 visits]

    Secondary Outcome Measures

    1. Measurement of oxidative stress [april to June 2009/ 3 visits]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    14 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Swimmer (at least 10h/week) aged from at least 14 years.
    Exclusion Criteria:
    • Smoker, obese or other disease which may interfere with the study. Some parts of the study may exclude swimmers taking inhaled corticosteroids.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Institut Universitaire de cardiologie et de pneumologie de Québec Québec Quebec Canada G1V 4G5

    Sponsors and Collaborators

    • Laval University

    Investigators

    • Principal Investigator: Louis-Philippe Boulet, MD, Laval University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Louis-Philippe Boulet, MD, Laval University
    ClinicalTrials.gov Identifier:
    NCT00876135
    Other Study ID Numbers:
    • proto nage 2
    First Posted:
    Apr 6, 2009
    Last Update Posted:
    May 13, 2013
    Last Verified:
    May 1, 2013
    Additional relevant MeSH terms:
    Respiratory Hypersensitivity
    Albuterol

    Study Results

    No Results Posted as of May 13, 2013